In the News
At this year’s Asembia Specialty Pharmacy Summit, one theme stood out: the growing momentum behind more direct ways…
“A huge challenge for healthcare leaders is that they are being asked to sustain high performance inside systems…
Will GLP-1 pills change how employers approach coverage? It’s an important question, but the answer isn't so straightforward.
On the surface, lower GLP-1 prices should make these therapies easier to manage. But as Rae McMahan, SVP…
Even with increased availability, access to GLP-1 therapies can be challenging for employers and healthcare consumers due to…
Access is the new standard – and with partners like Ilant Health, Prescryptive is delivering it. Our collaboration…
Prescription drug costs are among the fastest-growing and most unpredictable healthcare expenses employers face. According to recent data,…
Glucagon-like peptide-1 (GLP-1) therapies are reshaping care for diabetes, obesity, and cardiometabolic health. Yet with their rapid rise…
As healthcare costs continue to burden small businesses, voluntary prescription plans could be a compelling solution for employers…
Prescryptive’s SVP of Payer Solutions, Rae McMahan, offers timely insights in her new article in BenefitsPRO, “With tariffs in…
In a recent Newsweek article highlighting the surge of U.S. store closures—5,822 so far this year, compared to…
In a recent Drug Topics live interview at NCPDP 2025, Prescryptive’s SVP of Provider Solutions, Miranda Rochol, shares…